Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News
  • Published:

Funding crunch forces stem cell company to abandon therapies

Nature Biotechnology volume 25, pages 951–952 (2007)Cite this article

An Erratum to this article was published on 01 December 2007

ES Stem Cell International goes after medium-term revenues.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. San Francisco

    Monya Baker

Authors
  1. Monya Baker
    View author publications

    You can also search for this author in PubMed Google Scholar

Related links

Related links

Related links in Nature Research

The lure of stem-cell lines

US tosses out patents on three Wisconsin stem cell lines

Web links

ES Cell International

Singapore Agency for Science, Technology and Research (A*STAR)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baker, M. Funding crunch forces stem cell company to abandon therapies. Nat Biotechnol 25, 951–952 (2007). https://doi.org/10.1038/nbt0907-951

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0907-951

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing